JP2012500254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500254A5 JP2012500254A5 JP2011523481A JP2011523481A JP2012500254A5 JP 2012500254 A5 JP2012500254 A5 JP 2012500254A5 JP 2011523481 A JP2011523481 A JP 2011523481A JP 2011523481 A JP2011523481 A JP 2011523481A JP 2012500254 A5 JP2012500254 A5 JP 2012500254A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- salt
- group
- composition
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 15
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 13
- 235000018102 proteins Nutrition 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 12
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- XUHVCHNJCBBXMP-UHFFFAOYSA-M sodium;10-[(2-hydroxybenzoyl)amino]decanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCCCC([O-])=O XUHVCHNJCBBXMP-UHFFFAOYSA-M 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102000004877 Insulin Human genes 0.000 claims 6
- 108090001061 Insulin Proteins 0.000 claims 6
- 102000008847 Serpin Human genes 0.000 claims 6
- 108050000761 Serpin Proteins 0.000 claims 6
- 229940122618 Trypsin inhibitor Drugs 0.000 claims 6
- 101710162629 Trypsin inhibitor Proteins 0.000 claims 6
- 229940125396 insulin Drugs 0.000 claims 6
- 239000003001 serine protease inhibitor Substances 0.000 claims 6
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims 6
- 239000002753 trypsin inhibitor Substances 0.000 claims 6
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 5
- 108010011459 Exenatide Proteins 0.000 claims 4
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 229960001519 exenatide Drugs 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 108010039627 Aprotinin Proteins 0.000 claims 2
- 206010010144 Completed suicide Diseases 0.000 claims 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 102000051325 Glucagon Human genes 0.000 claims 2
- 108060003199 Glucagon Proteins 0.000 claims 2
- 235000010469 Glycine max Nutrition 0.000 claims 2
- 244000068988 Glycine max Species 0.000 claims 2
- 102000018997 Growth Hormone Human genes 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108010064983 Ovomucin Proteins 0.000 claims 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 2
- 102000035100 Threonine proteases Human genes 0.000 claims 2
- 108091005501 Threonine proteases Proteins 0.000 claims 2
- 229960004405 aprotinin Drugs 0.000 claims 2
- 239000003696 aspartic proteinase inhibitor Substances 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 239000002852 cysteine proteinase inhibitor Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000029087 digestion Effects 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 2
- 229960004666 glucagon Drugs 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 2
- 239000006014 omega-3 oil Substances 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8981208P | 2008-08-18 | 2008-08-18 | |
| US61/089,812 | 2008-08-18 | ||
| PCT/IL2009/000786 WO2010020978A1 (en) | 2008-08-18 | 2009-08-11 | Methods and compositions for oral administration of proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015004509A Division JP5981575B2 (ja) | 2008-08-18 | 2015-01-13 | タンパク質の経口投与用の方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012500254A JP2012500254A (ja) | 2012-01-05 |
| JP2012500254A5 true JP2012500254A5 (cg-RX-API-DMAC7.html) | 2012-09-27 |
| JP5740689B2 JP5740689B2 (ja) | 2015-06-24 |
Family
ID=41706898
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523481A Active JP5740689B2 (ja) | 2008-08-18 | 2009-08-11 | タンパク質の経口投与用の方法および組成物 |
| JP2015004509A Active JP5981575B2 (ja) | 2008-08-18 | 2015-01-13 | タンパク質の経口投与用の方法および組成物 |
| JP2016102778A Active JP6124095B2 (ja) | 2008-08-18 | 2016-05-23 | タンパク質の経口投与用の方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015004509A Active JP5981575B2 (ja) | 2008-08-18 | 2015-01-13 | タンパク質の経口投与用の方法および組成物 |
| JP2016102778A Active JP6124095B2 (ja) | 2008-08-18 | 2016-05-23 | タンパク質の経口投与用の方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US9186412B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3741359A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5740689B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102123697B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009283821B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2734442C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2823233T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1214153A1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ591497A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2494755C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010020978A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5222727B2 (ja) * | 2005-09-06 | 2013-06-26 | オーラメッド・ファーマスーティカルズ・インコーポレイテッド | タンパク質を経口投与するための方法及び組成物 |
| CA2719272C (en) | 2008-03-26 | 2020-08-18 | Oramed Ltd. | Methods and compositions for oral administration of proteins |
| US20110046053A1 (en) | 2008-05-05 | 2011-02-24 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
| NZ591497A (en) * | 2008-08-18 | 2012-11-30 | Entera Bio Ltd | A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment |
| NZ591810A (en) | 2008-09-17 | 2012-12-21 | Chiasma Inc | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid |
| HUP0900482A2 (en) * | 2009-08-03 | 2011-03-28 | Cera Med Kft | Pharmaceutical formulation for oral administration |
| US8759284B2 (en) | 2009-12-24 | 2014-06-24 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| MX2013000314A (es) | 2010-07-09 | 2013-01-29 | Affibody Ab | Polipeptidos. |
| PT2651398T (pt) | 2010-12-16 | 2018-03-09 | Novo Nordisk As | Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| MY161450A (en) | 2011-04-12 | 2017-04-14 | Novo Nordisk As | Double-acylated glp-1 derivatives |
| WO2013102899A1 (en) * | 2012-01-03 | 2013-07-11 | Oramed Ltd. | Methods and compositions for treating diabetes |
| US10342764B2 (en) | 2012-02-01 | 2019-07-09 | Oramed Ltd. | Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same |
| EP4324475A1 (en) * | 2012-03-22 | 2024-02-21 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
| DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
| EP2827845B1 (en) * | 2012-03-22 | 2018-12-26 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
| KR102266299B1 (ko) * | 2012-03-22 | 2021-06-18 | 노보 노르디스크 에이/에스 | Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조 |
| EP2830665A1 (en) * | 2012-03-28 | 2015-02-04 | Affibody AB | Oral administration |
| CN104487056A (zh) * | 2012-06-20 | 2015-04-01 | 诺和诺德A/S（股份有限公司） | 包含肽和递送剂的片剂制剂 |
| CN111763247B (zh) | 2012-09-25 | 2024-09-13 | 阿菲博迪公司 | 白蛋白结合多肽 |
| EP2941267B1 (en) * | 2013-01-03 | 2022-11-16 | Oramed Ltd. | Compositions for use in treating nafld |
| PL2991671T3 (pl) | 2013-05-02 | 2019-01-31 | Novo Nordisk As | Doustne dawkowanie związków glp-1 |
| CN104707131A (zh) * | 2013-12-13 | 2015-06-17 | 上海建华精细生物制品有限公司 | 一种药物组合物及其制备方法和用途 |
| WO2015091957A1 (en) | 2013-12-20 | 2015-06-25 | Affibody Ab | Engineered albumin binding polypeptide |
| IL285440B1 (en) | 2014-12-10 | 2025-09-01 | Amryt Endo Inc | Oral preparations containing octreotide in combination with other medicinal substances for the treatment of acromegaly |
| US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| CN107205949A (zh) * | 2015-01-29 | 2017-09-26 | 诺和诺德股份有限公司 | 包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物 |
| EP4527456A3 (en) | 2015-02-03 | 2025-05-21 | Amryt Endo, Inc. | Treating acromegaly with oral octreotide |
| WO2016128970A1 (en) | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Treatment of hypoparathyroidism |
| ES2784703T3 (es) | 2015-07-08 | 2020-09-30 | Research & Business Found Sungkyunkwan Univ | Derivados de la pirrolidina carboxamida y métodos para preparar y utilizar la misma |
| US20170189363A1 (en) * | 2015-12-30 | 2017-07-06 | Noven Pharmaceuticals, Inc. | Gastric acid modulators for oral delivery of peptides and proteins |
| EP3445356B1 (en) | 2016-04-22 | 2021-06-30 | Receptor Holdings, Inc. | Fast-acting plant-based medicinal compounds and nutritional supplements |
| EP3500291A4 (en) | 2016-08-17 | 2020-03-11 | Entera Bio Ltd. | FORMULA FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES |
| EA201892396A1 (ru) * | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
| US20180271792A1 (en) * | 2017-03-23 | 2018-09-27 | Rezolute, Inc. | Oral delivery of physiologically active substances |
| CN108653233A (zh) * | 2017-04-01 | 2018-10-16 | 苏州苏融生物医药有限公司 | 一种具有生物粘附性载多肽蛋白类药物固体颗粒物、包含其的制剂、制备方法及用途 |
| CN108653719A (zh) * | 2017-04-01 | 2018-10-16 | 苏州苏融生物医药有限公司 | 一种具有粘液穿透性载多肽蛋白类药物固体颗粒物、包含其的制剂、制备方法及用途 |
| CN108653234B (zh) * | 2017-04-01 | 2021-02-26 | 中国科学院上海药物研究所 | 载有多肽蛋白类药物的固体颗粒物及包含该颗粒物的双肠溶固体制剂、其制备方法及用途 |
| WO2019042247A1 (zh) * | 2017-08-28 | 2019-03-07 | 江苏恒瑞医药股份有限公司 | 一种cyp17抑制剂的药物组合物及其制备方法 |
| JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| CN109260464B (zh) * | 2018-10-29 | 2021-10-15 | 兆科药业（合肥）有限公司 | 抗血小板溶栓素的新用途 |
| MX2021005807A (es) | 2018-11-19 | 2021-07-02 | Receptor Holdings Inc | Aminoacidos grasos n-acilados para reducir la variabilidad de absorcion en composiciones basadas en cannabinoides. |
| JP7610410B2 (ja) * | 2019-03-08 | 2025-01-08 | アニヤ バイオファーム インク． | 副甲状腺ホルモンアナログの経口製剤および治療 |
| EP4025192B1 (en) | 2019-09-02 | 2025-12-03 | Novo Nordisk A/S | Process for producing a tablet comprising glp-1 peptides |
| EP4025240B1 (en) * | 2019-09-03 | 2024-10-30 | Amgen Inc. | Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof |
| EP4054536A1 (en) | 2019-11-07 | 2022-09-14 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| CN115209910A (zh) * | 2020-03-18 | 2022-10-18 | 四川海思科制药有限公司 | 口服药物组合物 |
| CN115461044B (zh) | 2020-04-29 | 2025-06-10 | 诺和诺德股份有限公司 | 包含glp-1激动剂和组氨酸的固体组合物 |
| CN111909955B (zh) * | 2020-08-10 | 2021-12-31 | 安徽新熙盟生物科技有限公司 | 重组MANNase-GLP-1及同源物的制备及应用 |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| CN113117050B (zh) * | 2021-05-06 | 2022-04-26 | 合肥天汇孵化科技有限公司 | 多肽组合物及其用途 |
| CN113171446B (zh) * | 2021-05-06 | 2022-03-29 | 合肥天汇孵化科技有限公司 | 利拉鲁肽组合物及其用途 |
| JP2024525377A (ja) | 2021-07-15 | 2024-07-12 | ノヴォ ノルディスク アー／エス | Ｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む錠剤 |
| KR20240063870A (ko) | 2021-08-23 | 2024-05-10 | 유니-파마 클레온 세티스 파메스티컬 레보라토리스 에스.에이. | 캡슐화된 생활성 거대분자를 갖는 리오트로픽 액정성 나노시스템 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5426616A (en) | 1977-07-30 | 1979-02-28 | Fujitsu Ltd | Input level monitor system for level adjuster and automatic restoration system for level adjuster |
| JPS5740689A (en) | 1980-08-25 | 1982-03-06 | Tokyo Shibaura Electric Co | Nuclear reactor shutdown device |
| IL68769A (en) * | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
| JPS60224638A (ja) * | 1984-04-23 | 1985-11-09 | Kao Corp | 経皮吸収促進剤およびこれを含有する外用剤 |
| US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
| US6692766B1 (en) * | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| AU712222B2 (en) * | 1995-03-31 | 1999-11-04 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5824638A (en) * | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| WO1998005351A1 (en) * | 1996-08-08 | 1998-02-12 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
| US5773647A (en) * | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| JP2001240558A (ja) | 2000-02-29 | 2001-09-04 | Nippon Suisan Kaisha Ltd | 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。 |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| EP1397156B1 (en) * | 2001-06-01 | 2007-03-14 | Novartis AG | Oral administration of parathyroid hormone and calcitonin |
| US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| ES2465496T3 (es) * | 2003-01-06 | 2014-06-05 | Emisphere Technologies, Inc. | Terapia de insulina oral nocturna |
| GB0308734D0 (en) * | 2003-04-15 | 2003-05-21 | Axcess Ltd | Uptake of macromolecules |
| EP1643978A1 (en) * | 2003-07-04 | 2006-04-12 | Nycomed Danmark A/S | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| PL1651249T3 (pl) * | 2003-07-23 | 2013-04-30 | Novartis Ag | Zastosowanie kalcytoniny w zapaleniu kości i stawów |
| JP2005281231A (ja) * | 2004-03-30 | 2005-10-13 | Bioserentack Co Ltd | 小腸ターゲットタイプの経口ｄｄｓ製剤 |
| JP2007532629A (ja) * | 2004-04-15 | 2007-11-15 | キアスマ， インコーポレイテッド | 生物学的障壁を横切る透過を促進し得る組成物 |
| JP2007536268A (ja) | 2004-05-06 | 2007-12-13 | エミスフェアー・テクノロジーズ・インク | 固体剤形の湿性ヘパリン |
| EP1789075A4 (en) * | 2004-08-25 | 2009-07-01 | Uab Research Foundation | ABSORPTION ENHANCER FOR DRUG ADMINISTRATION |
| JP2006111558A (ja) | 2004-10-14 | 2006-04-27 | Bioserentack Co Ltd | 多層構造を有する錠剤状の小腸粘膜付着性経口製剤 |
| EP1843755B1 (en) * | 2005-02-01 | 2015-04-01 | Emisphere Technologies, Inc. | Gastric retention and controlled release delivery system |
| WO2006103657A2 (en) | 2005-03-31 | 2006-10-05 | Dexcel Pharma Technologies Ltd. | A solid composition for intra-oral delivery of insulin |
| JP5222727B2 (ja) | 2005-09-06 | 2013-06-26 | オーラメッド・ファーマスーティカルズ・インコーポレイテッド | タンパク質を経口投与するための方法及び組成物 |
| US8927015B2 (en) | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| ES2538254T3 (es) * | 2006-04-18 | 2015-06-18 | Emisphere Technologies, Inc. | Agentes de administración de dialquil éter |
| NZ591497A (en) * | 2008-08-18 | 2012-11-30 | Entera Bio Ltd | A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment |
-
2009
- 2009-08-11 NZ NZ591497A patent/NZ591497A/xx unknown
- 2009-08-11 JP JP2011523481A patent/JP5740689B2/ja active Active
- 2009-08-11 EP EP20186801.5A patent/EP3741359A1/en active Pending
- 2009-08-11 ES ES09807991T patent/ES2823233T3/es active Active
- 2009-08-11 AU AU2009283821A patent/AU2009283821B2/en active Active
- 2009-08-11 RU RU2011108334/15A patent/RU2494755C2/ru active
- 2009-08-11 CA CA2734442A patent/CA2734442C/en active Active
- 2009-08-11 US US13/058,259 patent/US9186412B2/en active Active
- 2009-08-11 WO PCT/IL2009/000786 patent/WO2010020978A1/en not_active Ceased
- 2009-08-11 EP EP09807991.6A patent/EP2331072B8/en active Active
- 2009-08-11 CN CN200980132155.8A patent/CN102123697B/zh active Active
-
2013
- 2013-07-04 RU RU2013130611A patent/RU2646828C2/ru active
-
2015
- 2015-01-13 JP JP2015004509A patent/JP5981575B2/ja active Active
- 2015-11-10 US US14/936,758 patent/US10010503B2/en active Active
-
2016
- 2016-02-25 HK HK16102178.2A patent/HK1214153A1/zh unknown
- 2016-05-23 JP JP2016102778A patent/JP6124095B2/ja active Active
-
2018
- 2018-06-06 US US16/000,966 patent/US10420721B2/en active Active
-
2019
- 2019-08-21 US US16/546,375 patent/US11246827B2/en active Active
-
2022
- 2022-01-31 US US17/588,377 patent/US12311051B2/en active Active
-
2025
- 2025-05-25 US US19/218,293 patent/US20250281396A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500254A5 (cg-RX-API-DMAC7.html) | ||
| RU2011108334A (ru) | Способы и композиции для перорального введения белков | |
| CA3083198A1 (en) | Methods and compositions for oral administration of proteins | |
| JP2016505613A5 (cg-RX-API-DMAC7.html) | ||
| RU2010146372A (ru) | Композиции и способы перорального введения эксенатида | |
| JP2018197240A5 (cg-RX-API-DMAC7.html) | ||
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 | |
| AU2020203101B2 (en) | Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability | |
| JP2018504444A5 (ja) | 医薬組成物 | |
| JP2018504445A5 (cg-RX-API-DMAC7.html) | ||
| JP2008518943A5 (cg-RX-API-DMAC7.html) | ||
| JP2015145410A5 (cg-RX-API-DMAC7.html) | ||
| HRP20140185T1 (hr) | Peptidi i njihova primjena | |
| HRP20180425T1 (hr) | Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline | |
| EP2341065A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4a protease | |
| HK1247835A1 (zh) | 甲状旁腺功能减退症的治疗 | |
| RU2015132860A (ru) | Композиции инсулинов длительного действия | |
| WO2008021956A3 (en) | Acylaminoheteroaryl hepatitis c virus protease inhibitors | |
| JP2015509950A5 (cg-RX-API-DMAC7.html) | ||
| WO2004113365A3 (en) | Hepatitis c serine protease tri-peptide inhibitors | |
| JP2012515794A5 (cg-RX-API-DMAC7.html) | ||
| WO2009076166A3 (en) | Oximyl hcv serine protease inhibitors | |
| RU2020123357A (ru) | Пептиды, имеющие протеазную активность, для применения при лечении или профилактике коронавирусной инфекции | |
| DK2186830T3 (da) | Polyethylenglycol modificeret interferon alpha 2B og fremstillingsfremgangsmåde og applikationer deraf | |
| RU2006132719A (ru) | Способ повышения биологической доступности оспемифена |